Carfilnat (Carfilzomib Vials) 60mg

Carfilnat (Carfilzomib) 60mg vials are used for multiple myeloma treatment. This proteasome inhibitor supports cancer therapy regimens. Available in India, it is prescribed under medical supervision for targeted oncology care. Short-term storage guidance may apply.

Strength

60mg

Manufacturer / TM Owner

NATCO PHARMA LTD

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Carfilzomib is a proteasome inhibitor primarily used in the treatment of multiple myeloma, a type of blood cancer. It is often prescribed for patients who have received at least one prior therapy. The medication works by blocking proteasomes, which helps slow cancer cell growth. It may be used alone or combined with other cancer treatments.

Side Effects

Carfilzomib is administered intravenously and may cause fatigue, nausea, or fever as common effects. Some patients report low blood cell counts, which can increase infection risk. Swelling in the legs or shortness of breath may occur in some cases. Regular monitoring is advised during therapy.

Precautions & Warnings

Carfilzomib should be handled with care and administered by healthcare professionals. Patients with heart, kidney, or liver conditions should inform their doctor before use. Avoid exposure to infections and stay hydrated during treatment. Keep vials refrigerated until use unless otherwise directed.

Avoid Interactions

Carfilzomib may interact with other medications, including blood pressure drugs and diuretics. Strong CYP3A4 inhibitors or inducers can affect its levels in the body. Alcohol and herbal supplements should be used cautiously. Always disclose all medications to your healthcare provider before starting therapy.

References

Frequently Asked Questions

Carfilzomib is used to treat multiple myeloma, a type of blood cancer, often after other therapies.

Carfilzomib is given as an intravenous injection by a healthcare professional.

Common effects include fatigue, nausea, fever, and low blood cell counts.

No, it must be administered under medical supervision in a clinical setting.

Yes, Carfilzomib is manufactured in India and available as Carfilnat 60mg vials.

Published by GNH India Pharmaceuticals Limited

Last updated: 17 Jun 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.